Corporate Governance
The Company has opted for a one-tier governance structure. The Board of Directors is the ultimate decision-making body of the Company, except with respect to those areas that are reserved by law or by the Company’s Articles of Association to the Shareholders’ Meeting. The corporate governance of the Company is structured pursuant to Belgian Code of the Companies and Associations (the “CCA”), the Company's articles of association, and the Company's corporate governance charter adopted in accordance with the Belgian Corporate Governance Code 2020.
Board Of Directors
The Board of Directors currently consists of nine members. The directors have been appointed at the Shareholders Meeting of the Company. The Board’s composition reflects a diverse and complementary range of experience, nationalities and cultures, ensuring that the interests of all shareholders are taken into account. Members of the BoD are chosen for their skills, their integrity and their independence of mind.
Michel Lussier¹, Chairman, Non-executive director
Chris Buyse, Non-executive director
Serge Goblet, Non-executive director
Rudy Dekeyser², Non-executive director
Marina Udier, Independent director
Hilde Windels, Independent director
Filippo Petti, Executive director
Maria Koehler, Independent director
Dominic Piscitelli, Independent director
¹permanent representative of Mel Management SRL
²permanent representative of R.A.D. Lifesciences BVBA
Committees of the board of directors
The Board of Directors has set up committees to analyze and advise the Board of Directors on specific matters. Such committees are advisory bodies only and the decision-making remains the collegiate responsibility of the Board of Directors.
The Board of Directors has set-up a Nomination and Remuneration Committee composed of Michel Lussier (Chairman), Dominic Piscitelli, Hilde Windels and Filippo Petti (invited member).
The Board of Directors has set-up an Audit Committee composed of Dominic Piscitelli (Chairman), Chris Buyse and Hilde Windels.
Executive COMMITTEE
The Board of Directors has established an Executive Committee composed of the "Chief Executive officer" (CEO) and "Chief Financial Officer" (CFO), who is the chairman of the Executive Committee, the "Vice President Clinical Development & Medical Affaires", the "Chief Scientific Officer" (CSO), the "Chief Legal Officer" (CLO), the "Vice President Human Resources" and the "Chief Business Officer" (CBO). The Executive Committee discusses and consults with the Board of Directors on the day-to-day management of the Company in accordance with the Company's values, strategy, general policy and budget, as determined by the BoD.
Filippo Petti, Chief Executive Officer, CFO
Frédéric Lehmann3, VP Medical Affairs and Clinical Development
Stephen Rubino, Chief Business Officer
David Gilham, Chief Scientific Officer
Philippe Dechamps1, Chief Legal Officer
Philippe Nobels2, VP of Human Resources
1. Permanent representative of Nanda Devi SRL
2. Permanent representative of MC Consult SRL
3. Permanent representative of ImXsense SRL
